sponsored
PatientsVille.com Logo

PatientsVille

Vesicare Medical Research Studies

Up-to-date List of Vesicare Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Vesicare Medical Research Studies

Rank Status Study
1 Unknown  Solifenacin Succinate (Vesicare) for the Treatment of Overactive Bladder in Parkinson's Disease
Condition: Overactive Bladder in Parkinson's Disease
Interventions: Drug: solifenacin succinate (Vesicare);   Drug: placebo
Outcome Measures: The primary objective of this study is to measure the efficacy of solifenacin succinate (Vesicare) in reducing the mean number of micturitions per 24 hour period in Parkinson's disease (PD) patients as measured by voiding diaries.;   To examine the effect of solifenacin succinate (Vesicare) on urinary incontinence severity;   To examine the effect of solifenacin succinate (Vesicare) on Parkinson's disease severity;   To examine the effect of solifenacin succinate (Vesicare) on quality of life
2 Recruiting A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)
Conditions: Urinary Bladder Overactive;   Urinary Bladder Diseases;   Urologic Diseases
Interventions: Drug: Mirabegron;   Drug: Solifenacin succinate low dose;   Drug: Solifenacin succinate high dose
Outcome Measures: Change from Baseline in mean number of incontinence episodes per 24 hours;   Change from baseline in mean number of micturitions per 24 hours;   Number of incontinence episodes reported over 3-day diary;   Change from baseline in mean volume voided per micturition;   Change from baseline in mean number of urgency incontinence episodes per 24 hours;   Number of urgency incontinence episodes reported over 3-day diary;   Change from baseline in mean number of urgency episodes (grade 3 or 4) per 24 hours;   Change from baseline in mean number of pads per 24 hours;   Number of pads reported over 3-day diary;   Change from baseline in mean number of nocturia Episodes reported in 3-day diary;   Number of nocturia episodes reported over 3-day diary;   Proportion of subjects with at least a 50% decrease from Baseline in mean number of incontinence episodes per 24 hours;   Proportion of subjects with zero incontinence episodes per 24 hrs at End of Treatment;   Proportion of subjects with a mean of less than 8 micturitions per 24 hours at End of Treatment;   Change from baseline in total Euroqol European Quality of Life-5 Dimensions (EQ-5D) score (and subscale scores);   Change from baseline in total OAB-q score (and subscale scores);   Proportion of responders with at least a 10-point improvement from Baseline in OAB-q subscales;   Change from baseline in Treatment Satisfaction - Visual Analogue Scale (TS-VAS) score;   Change from baseline in Patient Perception Bladder Control (PPBC) score;   Proportion of subjects with at least a 1-point improvement from baseline in PPBC;   Proportion of subjects with major (at least 2-point) improvement from baseline in PPBC;   Patient and Clinician Global Impression of Change Scales (PGIC and CGIC)
3 Recruiting Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects
Conditions: Healthy Subjects;   Pharmacokinetics;   Drug-Drug Interaction (DDI)
Interventions: Drug: Mirabegron;   Drug: Solifenacin;   Drug: Digoxin
Outcome Measures: Pharmacokinetic parameter for digoxin (plasma) in the absence and presence of solifenacin and mirabegron: Cmax;   Pharmacokinetic parameter for digoxin (plasma) in the absence and presence of solifenacin and mirabegron: AUCtau;   Pharmacokinetic parameter for digoxin (plasma): Ctrough;   Pharmacokinetic parameter for digoxin (plasma): tmax, CL/F, PTR;   Pharmacokinetic parameter for digoxin (urine): Aetau, CLR, Aetau%;   Pharmacokinetic parameter for solifenacin and mirabegron (plasma): Ctrough;   Pharmacokinetic parameter for solifenacin and mirabegron (plasma): Cmax, AUCtau, tmax, CL/F;   Pharmacokinetic parameter for solifenacin and mirabegron (plasma): Cpredose;   Genotyping for CYP2D6;   Safety as assessed by adverse events, physical examination, vital signs, 12-lead ECG and laboratory tests
4 Recruiting Vesicare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate
Condition: Over-Active Bladder
Interventions: Drug: Solifenacin succinate;   Drug: Placebo
Outcome Measure: Change from baseline to end of study measured by the American Urology Association Symptom Score Questionnaire (AUASS).
5 Recruiting Comparisons of 3-month Versus 6-month Solifenacin Treatment for Female OAB Patients
Condition: Overactive Bladder
Interventions: Drug: Solifenacin for 12 weeks;   Drug: Solifenacin for 24 weeks
Outcome Measures: The rate of normalized urodynamic findings;   The cure rate of overactive bladder;   The recurrence rate of overactive bladder;   The difference of urine nerve growth factor level
6 Recruiting This is a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder
Conditions: Overactive Bladder;   Urgency Incontinence;   Urinary Bladder Overactive;   Urinary Bladder DiseasesUrologic Diseases
Interventions: Drug: Solifenacin Succinate;   Drug: Mirabegron;   Drug: Placebo
Outcome Measures: Change from baseline in mean number of incontinence episodes per 24 hours at End of Treatment (EoT);   Change from baseline in mean number of micturitions per 24 hours at EoT;   Change from baseline in mean volume voided per micturition at EoT;   Change from baseline in Symptom Bother as assessed by Overactive Bladder Questionnaire (OAB-q) at EoT;   Change from baseline in Subject assessment of Treatment Satisfaction-Visual Analogue Scale (TS-VAS) at EoT;   Number of incontinence episodes during the 7-day observation period prior to week 4, 8, 12 and EoT and changes from baseline;   Change from baseline in mean number of incontinence episodes per 24 hours at secondary time points (after 4, 8 and 12 weeks of treatment);   Change from baseline in mean number of micturitions per 24 hours at secondary time points (after 4, 8 and 12 weeks of treatment);   Change from baseline in mean volume voided at secondary time points (after 4, 8 and 12 weeks of treatment);   Number of urgency incontinence episodes during the 7-day observation period prior to week 4, 8, 12 and EoT and changes from baseline;   Change from baseline in mean number of urgency incontinence episodes per 24 hours (Week 4, 8, 12, and EoT);   Change from baseline in mean number of urgency episodes (grade 3 and/or 4)/24 hours (PPIUS scale) (Week 4, 8, 12, and EoT);   Number of nocturia episodes during the 7-day observation period prior to Week 4, 8, 12, and EoT and changes from baseline;   Change from baseline in mean number of nocturia episodes per 24 hours(Week 4, 8, 12, and EoT);   Number of pads used during the 7-day observation period prior to Week 4, 8, 12, and EoT and changes from baseline;   Change from baseline in mean number of pads used per 24 hours (Week 4, 8, 12, and EoT);   Number of incontinence-free days during the 7-day diary period (Week 4, 8, 12, and EoT);   Number of days with less than 8 micturitions during the 7-day diary period (Week 4, 8, 12, and EoT);   Number of incontinence-free days with less than 8 micturitions per day during the 7-day diary period (Week 4, 8, 12, and EoT)
7 Not yet recruiting A Study to Evaluate Quality of Life in Patients Switched to Solifenacin From Other Antimuscarinics
Condition: Urinary Bladder, Overactive
Intervention: Drug: Solifenacin
Outcome Measures: Change from baseline of Over Active Bladder questionnaire Short Form (OAB-q SF) score;   Change from baseline of Patient Assessment of Treatment Satisfaction (TS-VAS);   Change from baseline in EuroQol Group system (EQ-5D-5L) score;   Change in QoL according to previous antimuscarinic treatment and sex (assessed by: TS-VAS score, OAB-q SF score, EQ-5D-5L);   Change from baseline in OAB symptoms assessed by micturition diary;   Persistence to therapy (measured by proportion of Days Covered (PDC, threshold of 80 percent during the measurement period), median length of therapy (days));   Occurence of adverse drug reaction
8 Recruiting Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
Conditions: Hot Flashes;   Breast Cancer
Interventions: Drug: solifenacin;   Drug: Clonidine
Outcome Measures: hot flash composite and frequency scores (daily diary);   number of clinician-rated adverse events;   daily functioning (Hot Flash-Related Daily Interference score);   sleep (Insomnia Severity Index);   quality of life (Illness Cognition Questionnaire, SF-12)
9 Recruiting Therapy of the Overactive Bladder Syndrome
Condition: Overactive Bladder
Interventions: Drug: solifenacin;   Procedure: PFMT and WBVT
Outcome Measures: Change of patient perception of bladder condition (PPBC);   Change in micturitions/24h based on a 3-day micturition diary;   Change of urgency episodes (grade ≥3) /24h;   Change in volume voided per micturition;   Change in number of incontinence and urge incontinence episodes/24h;   Change in number of pads used/24h
10 Recruiting A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients
Condition: Overactive Bladder
Interventions: Drug: mirabegron;   Drug: solifenacin
Outcome Measures: Safety assessed by the incidence of adverse events, vial signs labo-tests, 12-lead ECGs, QTc-intervals Urine volume and uroflowmetry;   Change from baseline in OABSS (OverActive Bladder Symptom Score);   Change from baseline in OAB-q (OverActive Bladder questionnaire) short form (QAB-q SF) score;   Change from baseline in mean number of micturition episodes per 24 hour;   Change from baseline in mean number of urgency episodes per 24 hours;   Change from baseline in mean number of urinary incontinence episodes per 24 hours;   Change from baseline in mean volume voided per micturition
11 Unknown  Solifenacin Succinate Versus Fesoterodine A Comparison Trial for Urgency Symptoms
Condition: Urinary Bladder, Overactive
Interventions: Drug: solifenacin succinate;   Drug: fesoterodine
Outcome Measures: Changes in urgency sensation;   Adverse events
12 Unknown  Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder
Conditions: Urinary Urge;   Urge Incontinence;   Overactive Bladder
Interventions: Drug: solifenacin succinate;   Drug: placebo
Outcome Measures: 15% reduction in the amount of voids in a 24 hour period;   Assessing quality of life prior to treatment with respect to urge symptoms, then monitoring for improvement after treatment.
13 Unknown  A Study to Estimate the Efficacy and Safety of Solifenacin in Female With Stress Urinary Incontinence and Urgency Urinary Incontinence
Conditions: Stress Urinary Incontinence;   Urgency Urinary Incontinence
Intervention: Drug: solifenacin
Outcome Measures: Changes in the number of urge urinary incontinence episodes per 24 hours between baseline and week 12;   Percent change in the mean number of urge urinary incontinence episodes per 24 hours;   Change in the mean number of urge urinary incontinence episodes per 24 hours;   Change in the mean frequency of urination per 24 hours;   Percent change in the mean frequency of urination;   Changes in the mean and sum rating on the Bladder Sensation Scale per 24 hours;   Change in the mean number of severe urgency episodes per 24 hours;   Changes in overactive bladder symptom score (OABSS) questionnaire;   Changes in short urogenital distress inventory (UDI-6);   Changes in short incontinence impact questionnaire (IIQ-7);   Safety assessed by the incidence and severity of side effects
14 Recruiting A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 2 Years to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)
Conditions: Neurogenic Detrusor Overactivity;   Pediatric
Intervention: Drug: Solifenacin succinate
Outcome Measures: Change from baseline in maximum cystometric capacity (MCC) during treatment at week 24;   Change from baseline to optimal dose at steady state (as confirmed by urodynamics at weeks 3, 6, 9 or 12);   Change from baseline to week 24 (as confirmed by urodynamics;   Change from baseline to week 52 (optional) in MCC;   Change from baseline to week 52 (optional) in bladder compliance (∆V/∆Pdet (Detrusor pressure));   Change from baseline to week 52 (optional) in end-filling pressure when filling is stopped;   Change from baseline to week 52 (optional) in End-filling pressure 5 min after filling is stopped;   Change from baseline to week 52 (optional) in Volume at end of filling and 5 min after end of filling;   Change from baseline to week 52 (optional) in bladder volume at first detrusor contraction (> 15 cm H2O (water));   Change from baseline to week 52 (optional) in bladder volume at 10, 20 and 30 cm H2O detrusor pressure (Pdet), given that the pressures are reached during the examination;   Change from baseline to week 52 (optional) in number of overactive detrusor contractions (> 15 cm H2O) during filling;   Change from baseline each post-baseline visit (week 3 up to week 52) in average catheterized volume per catheterization;   Change from baseline each post-baseline visit (week 3 up to week 52) in maximum catheterized volume per day;   Change from baseline each post-baseline visit (week 3 up to week 52) in mean number of periods between the CICs (Clean Intermittent Catheterization) with incontinence (leakage where a diaper is not used, or dampness where a diaper is used), per 24 hours;   Change from baseline each post-baseline visit (week 3 up to week 52) in mean number of day-time periods between the CICs with incontinence, per 24 hours;   Change from baseline each post-baseline visit (week 3 up to week 52) in mean number of night-time periods between the CICs with incontinence;   Change from baseline (Day-1) to Visit 9 (Week 52) in Infant/Toddler Quality of Life (ITQoL)
15 Recruiting Effect of Electroacupuncture Versus PFMT Plus Solifenacin for Mixed Urinary Incontinence
Condition: Urinary Incontinence
Interventions: Procedure: acupuncture;   Drug: solifenacin;   Procedure: PFMT
Outcome Measures: Percentage of change from baseline in 72-h incontinence episode frequency (IEF) (week 12);   Percentage of change from baseline in 72-h IEF;   Percentage of participants with ≥50% decrease in average 72-h incontinence episode frequency;   Change from baseline in 72-h incontinence episode frequency;   Change from baseline in the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) score;   Change from baseline in the amount of urine leakage;   Change from baseline in average 72-h urgencies/urination/nocturia episodes;   Change from the baseline in the number of pads used in one week;   Percentage of change from the baseline in 72-h IEF of subgroups;   Satisfaction degree;   Patient global impression improvement;   Electroacupuncture acceptance assessment
16 Unknown  The Effect of Solifenacin on Post Void Dribbling in Women
Conditions: Postvoid Dribbling;   Incontinence;   Post Micturition Dribble
Intervention: Drug: solifenacin
Outcome Measures: The percent reduction in post void dribbling episodes (events);   the percent of patients with at least 50% reduction in post void dribbling episodes;   patients perspective of the impact of their disease, captured using the pelvic floor distress inventory
17 Recruiting Bacterial Genomic Sequencing in Overactive Bladder
Condition: Overactive Bladder
Intervention: Drug: Solifenacin
Outcome Measure: Bacterial Genomic Sequencing
18 Recruiting Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate)
Conditions: Overactive Bladder;   Benign Prostate Hyperplasia;   Transurethral Resection of Prostate;   Photoselective Vaporization Prostatectomy
Interventions: Drug: Solifenacin Succinate;   Drug: Placebo
Outcome Measures: Mean change from the baseline in the number of urgency episodes per 24 hrs in the voiding diary at Week 2;   Mean change from the baseline in the number of urgency episodes per 24 hrs in the voiding diary at Week 4;   Change from baseline in IPSS total score;   Changes from baseline in IPSS storage subscale score;   Changes from baseline in IPSS voiding subscale score;   Changes from baseline in individual IPSS scores;   Changes from baseline in IPSS QOL;   Changes from baseline in OABSS total score;   Change from baseline in average number of micturitions per 24 hrs for three days as recorded in the voiding diary;   Safety assessed by the incidence of adverse events, physical exam, and vital signs;   Urinal post voiding residual volume;   Maximum flow rate of the urine
19 Recruiting A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Patients 5 to 18 Years of Age With Neurogenic Detrusor Overactivity
Condition: Neurogenic Detrusor Overactivity
Intervention: Drug: Solifenacin succinate
Outcome Measures: Change from baseline in maximum cystometric capacity (MCC);   Change in Maximum Cystometric Capacity (MCC);   Change in Urodynamics;   Change in Diary Observations;   Change in Quality of Life
20 Recruiting The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Urinary Tract Infection in Females
Condition: Urinary Tract Infection
Interventions: Drug: Levofloxacin;   Drug: Solifenacin succinate;   Drug: Placebo (for Solifenacin succinate)
Outcome Measure: Number of participants with storage symptoms

These studies may lead to new treatments and are adding insight into Vesicare etiology and treatment.

A major focus of Vesicare research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Vesicare